Dr. Prasanth Ravipati, MD

Dr. Ravipati practices at Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System.

Dr. Ravipati's NPI, 1285048256, was assigned on June 17, 2014. Dr. Ravipati holds Minnesota license 67537.

Dr. Ravipati's primary practice is Nebraska Medical Center, at 988102 Nebrasks Medical Center, Omaha, NE 68198 in Douglas County. The practice phone is (402) 559-4000. Dr. Ravipati also practices at Nebraska Medical Center, 987400 Nebraska Medical Ctr, Omaha, NE 68198.

Dr. Ravipati's primary practice is Nebraska Medical Center in Omaha, Nebraska, part of University of Nebraska System. Dr. Ravipati is also affiliated with Bellevue Medical Center. The medical group on file is UNMC Physicians. Dmand AI also links Dr. Ravipati to 1 more dialysis center and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ravipati practices, 3 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Ravipati's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dmand AI has Dr. Ravipati's licenses on file in 2 states: Minnesota and Nebraska.

CMS data shows 421 Medicare services from Dr. Ravipati across 8 procedure codes in 2024, for 242 Medicare patients. Medicare paid $29,071 for them.

CMS counts 242 Medicare patients who saw Dr. Ravipati in 2024. The largest group is 65 to 74, with 117 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 19% are also on Medicaid. Their average risk score is 4.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ravipati's median patient age at 71, with 43% women.

In 2024, Dr. Ravipati wrote 383 Medicare Part D claims for 70 patients. 89% of them were for generic drugs. CMS names the drug for 300 of them, across 13 drugs with 11 or more claims each, at $29,022 in total drug cost. In 2023, CMS named 281 claims across 10 drugs.

Dr. Ravipati accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ravipati as offering telehealth.

Dmand AI links 6 papers to Dr. Ravipati, published from 2021 to 2025. 2022 was the busiest year, with 2. Dr. Ravipati has published most often in Glomerular Dis. Dr. Ravipati's most frequent co-authors are Patrick H. Nachman, MD, Pietro Alessandro Ambrogio Canetta, MD and Krzysztof Kiryluk, MD.

CMS Open Payments shows 26 general payments to Dr. Ravipati from 3 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 72% of the total. Travere Therapeutics, Inc. paid the most, $6,181.